Jeena Sikho Lifecare Limited has informed the Exchange about Investor Presentation
JSLL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Jeena Sikho Lifecare reported strong FY26 results with revenue of ₹801 crore (up 71% YoY) and EBITDA margin expanding to 44% from 30% in FY25. Q4FY26 revenue was ₹215.55 crore (up 55% YoY) with EBITDA margin at 36%, though sequentially lower than Q3FY26's 45% due to one-time provisions for labour code amendments, ESOP provisioning, and year-end performance bonuses. The company operates 61 hospitals and 58 clinics across 23 states with 2,861 total bed capacity (2,300 operational). IPD volumes grew 65% to 40,454 patients and OPD volumes grew 69% to ~5.7 lakh patients. The Board recommended a dividend of ₹4.50 per share. The business is split between Ayurveda Healthcare Services (₹385 crore, 48%) and Ayurveda Healthcare Products (₹416 crore, 52%), with a capital-light hub-and-spoke model generating 46% ROCE.
The company delivered exceptional full-year growth with margin expansion, though Q4 showed sequential moderation from one-time costs. The dividend recommendation and strong FY26 performance demonstrate shareholder-friendly governance. Investors should note the high concentration in Punjab/Uttar Pradesh and the unproven scalability of the Ayurvedic healthcare model at larger volumes.